Thursday, February 20, 2020

Tag: ReNetX Bio

ReNetX Bio Receives Fast Track Designation From U.S. FDA

Published: January 8, 2020

Potential First-in-Class Therapy for Chronic Spinal Cord Injury

NEW HAVEN, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) — ReNetX Bio announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for ReNetX Bio’s clinical therapy (AXER-204) for the potential treatment of Chronic Spinal Cord Injury (SCI).  ReNetX Bio is currently conducting a Phase 1/2 clinical trial “RESET” in patients with SCI, with topline results expected in 2021.

Drug aims to help treat spinal cord injuries

Published: July 25, 2017

Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its lead drug candidate to market.

ReNetX Bio is looking to guide its drug candidate, Nogo Trap, through its first round of clinical trials. Company officials say Nogo Trap is designed to help patients with chronic spinal cord injury.

Do NOT follow this link or you will be banned from the site!